Turoctocog alfa - Novo Nordisk

Drug Profile

Turoctocog alfa - Novo Nordisk

Alternative Names: N8; NN-7008; NNC-0155-0000-0004; NovoEight; Recombinant factor VIII - Novo Nordisk; rFVIII - Novo Nordisk; Zonovate

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 01 Dec 2016 Phase-III clinical trials in Haemophilia A (In children, In adults, In the elderly, Treatment-experienced) in China (IV) (NCT02938585)
  • 18 Oct 2016 Novo Nordisk plans the phase III guardian™ 7 trial for Haemophilia A (In children, In adults, In the elderly, Treatment-experienced) in China (IV) (NCT02938585)
  • 01 Oct 2016 Novo Nordisk initiates the phase I guardian™ 9 trial for Haemophilia A (In adults) in USA, Bulgaria, Germany and Taiwan (IV) (NCT02941354)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top